Infographic: Balancing Advancement And Affordability of High-Cost Pharmacy Benefits

The Integrated Benefits Institute’s (IBI) latest research delves into how high-cost therapies can be integrated into employee benefit plans. This analysis of GLP-1 medications and cell and gene therapy adoption provides a framework for understanding how novel therapies are adopted within employee benefits programs and highlights key patterns in organizational decision-making and adoption success.  

Highlights from IBI's study:

- 33% of employers currently include cell and gene therapies (CGTs) in their benefit plans.
- 36% are actively evaluating CGT coverage strategies.
- 58% of non-adopters are planning to implement CGT strategies in the next 24 months.
- Barriers to CGT strategy adoption include: financial concerns, overall lack of information available for clients, consultants not providing enough information, and employers do not see CGTs as an immediate concern.
- 90% of employers link CGT adoption with improved employee productivity.

View Infographic